Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

606 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).
Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN Jr, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. Ramalingam SS, et al. Among authors: salgia r. J Thorac Oncol. 2011 Oct;6(10):1741-5. doi: 10.1097/JTO.0b013e318225924c. J Thorac Oncol. 2011. PMID: 21716143 Free PMC article. Clinical Trial.
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI. Socinski MA, et al. Among authors: salgia r. Clin Cancer Res. 2013 Jun 1;19(11):3068-77. doi: 10.1158/1078-0432.CCR-12-3381. Epub 2013 Apr 3. Clin Cancer Res. 2013. PMID: 23553849 Free PMC article. Clinical Trial.
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.
Lara PN Jr, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR. Lara PN Jr, et al. Among authors: salgia r. Clin Cancer Res. 2015 Oct 1;21(19):4321-6. doi: 10.1158/1078-0432.CCR-14-3281. Epub 2015 Jun 23. Clin Cancer Res. 2015. PMID: 26106072 Free PMC article.
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
Carter CA, Rajan A, Keen C, Szabo E, Khozin S, Thomas A, Brzezniak C, Guha U, Doyle LA, Steinberg SM, Xi L, Raffeld M, Tomita Y, Lee MJ, Lee S, Trepel JB, Reckamp KL, Koehler S, Gitlitz B, Salgia R, Gandara D, Vokes E, Giaccone G. Carter CA, et al. Among authors: salgia r. Ann Oncol. 2016 Apr;27(4):693-9. doi: 10.1093/annonc/mdw008. Epub 2016 Jan 22. Ann Oncol. 2016. PMID: 26802155 Free PMC article.
Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
Vigneswaran J, Tan YH, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, Ferguson MK, Husain AN, Vokes EE, Salgia R. Vigneswaran J, et al. Among authors: salgia r. Oncotarget. 2016 Apr 5;7(14):18876-86. doi: 10.18632/oncotarget.7739. Oncotarget. 2016. PMID: 26934441 Free PMC article.
KRAS in Non-Small-Cell Lung Cancer-Reply.
Wood K, Hensing T, Salgia R. Wood K, et al. Among authors: salgia r. JAMA Oncol. 2016 Oct 1;2(10):1373-1374. doi: 10.1001/jamaoncol.2016.2347. JAMA Oncol. 2016. PMID: 27442777 No abstract available.
606 results